139277-58-0

Basic information

• Product Name: 4-BIPHENYLACETIC ACID HYDRAZIDE
• Synonyms: 4-BIPHENYLACETIC ACID HYDRAZIDE;4-BIPHENYLACETIC HYDRAZIDE;AKOS B015277;ART-CHEM-BB B015277;CHEMBRDG-BB 3015277;2-biphenyl-4-ylacetohydrazide(SALTDATA: FREE);2-(4-phenylphenyl)acetohydrazide;2-(4-phenylphenyl)ethanehydrazide
• CAS NO: 139277-58-0
• Molecular Formula: C₁₄H₁₄N₂O
• Molecular Weight: 226.27
• Mol File: 139277-58-0.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 473.9 °C at 760 mmHg
• Flash Point: 240.4 °C
• Appearance: /
• Density: 1.147 g/cm³
• Vapor Pressure: 3.79E-09mmHg at 25°C
• Refractive Index: 1.601
• CAS DataBase Reference: 4-BIPHENYLACETIC ACID HYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BIPHENYLACETIC ACID HYDRAZIDE(139277-58-0)
• EPA Substance Registry System: 4-BIPHENYLACETIC ACID HYDRAZIDE(139277-58-0)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 139277-58-0(Hazardous Substances Data)

Usage

General Description

4-BIPHENYLACETIC ACID HYDRAZIDE, also known as biphenylacetic acid hydrazide, is a chemical compound with potential use as a drug and anti-inflammatory agent. It has been studied for its ability to inhibit the production of leukotrienes, which are involved in inflammatory and allergic reactions in the body. 4-BIPHENYLACETIC ACID HYDRAZIDE has also been researched for its potential as an anti-cancer agent, with studies showing promising results in inhibiting the growth of certain cancer cells. The compound has also been investigated for its potential use in the treatment of respiratory and cardiovascular diseases. Additionally, 4-BIPHENYLACETIC ACID HYDRAZIDE has shown potential as an analgesic and antipyretic agent, making it a versatile compound with a range of potential applications in the medical field.

InChI:InChI=1/C14H14N2O/c15-16-14(17)10-11-6-8-13(9-7-11)12-4-2-1-3-5-12/h1-9H,10,15H2,(H,16,17)

Upstream product

• 39889-69-5 biphenyl-4-yl-acetyl chloride 
• 14062-23-8 4-biphenylylacetic acid ethyl ester 
• 5728-52-9 (4-biphenylyl)acetic acid 

Downstream Products

• 1489288-50-7 1-(4-biphenylacetyl)-4-cyclohexylbutyl-thiosemicarbazide 
• 1489288-73-4 1-(4-biphenylacetyl)-4-(4-chlorophenethyl)-thiosemicarbazide 
• 1260172-93-7 3-(biphenyl-4-yl-methyl)-4-(2-fluorophenyl)-5-methyl-4H-1,2,4-triazole 
• 1257330-58-7 5-(4-phenylbenzyl)-4-(4-phenylbenzyl)-2,4-dihydro[1,2,4]triazole-3-thiol potassium salt 
• 1257330-56-5 5-(4-phenylbenzyl)-4-(3-phenpropyl)-2,4-dihydro[1,2,4]triazole-3-thiol potassium salt 

Relevant articles and documents

Synthesis and structure-activity relationships of 3,4,5-trisubstituted-1,2,4-triazoles: High affinity and selective somatostatin receptor-4 agonists for Alzheimer's disease treatment

Somatostatin receptor-4 (SST4) is highly expressed in brain regions affiliated with learning and memory. SST4 agonist treatment may act to mitigate Alzheimer's disease (AD) pathology. An integrated approach to SST4 agonist lead optimization is presented herein. High affinity and selective agonists with biological efficacy were identified through iterative cycles of a structure-based design strategy encompassing computational methods, chemistry, and preclinical pharmacology. 1,2,4-Triazole derivatives of our previously reported hit (4) showed enhanced SST4 binding affinity, activity, and selectivity. Thirty-five compounds showed low nanomolar range SST4 binding affinity, 12 having a Ki 500-fold affinity for SST4 as compared to SST2A. SST4 activities were consistent with the respective SST4 binding affinities (EC50 600-fold selectivity over SST2A) display a favorable physiochemical profile, and was advanced to learning and memory behavior evaluations in the senescence accelerated mouse-prone 8 model of AD-related cognitive decline. Chronic administration enhanced learning with i.p. dosing (1 mg kg-1) compared to vehicle. Chronic administration enhanced memory with both i.p. (0.01, 0.1, 1 mg kg-1) and oral (0.01, 10 mg kg-1) dosing compared to vehicle. This study identified a novel series of SST4 agonists with high affinity, selectivity, and biological activity that may be useful in the treatment of AD. This journal is

3,4,5-TRISUBSTITUTED-1,2,4-TRIAZOLES AND 3,4,5-TRISUBSTITUTED-3-THIO-1,2,4-TRIAZOLES AND USES THEREOF

The present disclosure describes novel compounds that are somatostatin receptor type 4 agonists.

Aromatic hydrazides as specific inhibitors of bovine serum amine oxidase

New hydrazides were synthesized in search for specific inhibitors of bovine serum amine oxidase: a series of benzoic and phenylacetic acid hydrazides containing the 1H-imidazol-1-yl or the 1H-imidazol-1-ylmethyl group as (o,m,p)-substituent in the phenyl ring; an analogous series of p-substituted phenylhydrazides with 5 or 6-membered heterocyclic ring as substituent, and a series of similar phenylpropionic hydrazides. The longer and more flexible phenylacetic hydrazides, and to a somewhat lesser extent the phenylpropionic ones, were better specific inhibitors of bovine serum amine oxidase than the benzoic hydrazides, which were also bound by the enzyme with high affinity, but at a slow rate. Derivatives with p- and m-substituents were more reactive than the o-substituted ones. The chemical nature of the substituent was less important than its position in the phenyl ring and the presence of methylene spacers. These data point to the presence of a hydrophobic site at short distance from the protein carbonyl cofactor, so that simultaneous interaction of the 2 ends of the inhibitor molecule can occur at the 2 sites. The presence of the hydrophobic site was confirmed by the capability of some molecule deprived of the hydrazidic group to act as mild inhibitors. All hydrazides were less reactive by 2-3 orders of magnitude towards pig kidney diamine oxidase and FAD-dependent monoamine oxidase from rat brain mitochondria, while the other compounds showed similar inhibition power against all proteins. The specificity for the bovine enzyme seems therefore to be related to the concerted action of the 2 moieties of the inhibitor molecule.